Review





Similar Products

recombinant human igf 1  (MedChemExpress)
94
MedChemExpress recombinant human igf 1
Effects of BA on YY1/FAS, ERβ, <t>insulin/IGF‐1,</t> MAPK/ERK, and Notch signalling pathways regulating UBE2T expression in glioma cells. (A) WB assay show that BA suppresses the YY1/FAS axis, decreasing cleaved caspase‐8 and YY1 nuclear accumulation (red arrows); FASL co‐treatment failed to restore UBE2T (black arrows). (B) WB assay show that BA inhibits ERβ nuclear localization and ERK1/2 phosphorylation (red arrows); ERβ activation by DPN re‐stimulated p‐ERK1/2 and elevated UBE2T (red arrows). (C) WB assay show that the insulin/IGF‐1 pathway is unaffected by BA (black arrows), but IGF‐1 treatment enhances IGF‐1Rβ phosphorylation, increases p‐ERK1/2, and up‐regulates UBE2T (red arrows). (D) WB assay show that direct ERK activation (ERK agonist) increases UBE2T expression (red arrows), confirming ERK as a convergent effector. (E) BA does not alter Notch signalling, and DLL4‐Fc–induced Notch activation shows no impact on UBE2T. β‐Actin served as loading controls of total protein, and Lamin B1 for nuclear extracts. (F–H) The relative mRNA levels of UBE2T are detected by qPCR in U87MG (F), LN229 (G) and U251 glioma cell lines (H) additionally treated with agonists of the pathway mentioned above. “*” indicates significant difference compared with BA+CDDP group.
Recombinant Human Igf 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human igf 1/product/MedChemExpress
Average 94 stars, based on 1 article reviews
recombinant human igf 1 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant mouse igf  (Sino Biological)
94
Sino Biological recombinant mouse igf
Effects of BA on YY1/FAS, ERβ, <t>insulin/IGF‐1,</t> MAPK/ERK, and Notch signalling pathways regulating UBE2T expression in glioma cells. (A) WB assay show that BA suppresses the YY1/FAS axis, decreasing cleaved caspase‐8 and YY1 nuclear accumulation (red arrows); FASL co‐treatment failed to restore UBE2T (black arrows). (B) WB assay show that BA inhibits ERβ nuclear localization and ERK1/2 phosphorylation (red arrows); ERβ activation by DPN re‐stimulated p‐ERK1/2 and elevated UBE2T (red arrows). (C) WB assay show that the insulin/IGF‐1 pathway is unaffected by BA (black arrows), but IGF‐1 treatment enhances IGF‐1Rβ phosphorylation, increases p‐ERK1/2, and up‐regulates UBE2T (red arrows). (D) WB assay show that direct ERK activation (ERK agonist) increases UBE2T expression (red arrows), confirming ERK as a convergent effector. (E) BA does not alter Notch signalling, and DLL4‐Fc–induced Notch activation shows no impact on UBE2T. β‐Actin served as loading controls of total protein, and Lamin B1 for nuclear extracts. (F–H) The relative mRNA levels of UBE2T are detected by qPCR in U87MG (F), LN229 (G) and U251 glioma cell lines (H) additionally treated with agonists of the pathway mentioned above. “*” indicates significant difference compared with BA+CDDP group.
Recombinant Mouse Igf, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse igf/product/Sino Biological
Average 94 stars, based on 1 article reviews
recombinant mouse igf - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
igf 1 protein  (MedChemExpress)
93
MedChemExpress igf 1 protein
Effects of BA on YY1/FAS, ERβ, <t>insulin/IGF‐1,</t> MAPK/ERK, and Notch signalling pathways regulating UBE2T expression in glioma cells. (A) WB assay show that BA suppresses the YY1/FAS axis, decreasing cleaved caspase‐8 and YY1 nuclear accumulation (red arrows); FASL co‐treatment failed to restore UBE2T (black arrows). (B) WB assay show that BA inhibits ERβ nuclear localization and ERK1/2 phosphorylation (red arrows); ERβ activation by DPN re‐stimulated p‐ERK1/2 and elevated UBE2T (red arrows). (C) WB assay show that the insulin/IGF‐1 pathway is unaffected by BA (black arrows), but IGF‐1 treatment enhances IGF‐1Rβ phosphorylation, increases p‐ERK1/2, and up‐regulates UBE2T (red arrows). (D) WB assay show that direct ERK activation (ERK agonist) increases UBE2T expression (red arrows), confirming ERK as a convergent effector. (E) BA does not alter Notch signalling, and DLL4‐Fc–induced Notch activation shows no impact on UBE2T. β‐Actin served as loading controls of total protein, and Lamin B1 for nuclear extracts. (F–H) The relative mRNA levels of UBE2T are detected by qPCR in U87MG (F), LN229 (G) and U251 glioma cell lines (H) additionally treated with agonists of the pathway mentioned above. “*” indicates significant difference compared with BA+CDDP group.
Igf 1 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igf 1 protein/product/MedChemExpress
Average 93 stars, based on 1 article reviews
igf 1 protein - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
igf 1  (MedChemExpress)
93
MedChemExpress igf 1
Effects of BA on YY1/FAS, ERβ, <t>insulin/IGF‐1,</t> MAPK/ERK, and Notch signalling pathways regulating UBE2T expression in glioma cells. (A) WB assay show that BA suppresses the YY1/FAS axis, decreasing cleaved caspase‐8 and YY1 nuclear accumulation (red arrows); FASL co‐treatment failed to restore UBE2T (black arrows). (B) WB assay show that BA inhibits ERβ nuclear localization and ERK1/2 phosphorylation (red arrows); ERβ activation by DPN re‐stimulated p‐ERK1/2 and elevated UBE2T (red arrows). (C) WB assay show that the insulin/IGF‐1 pathway is unaffected by BA (black arrows), but IGF‐1 treatment enhances IGF‐1Rβ phosphorylation, increases p‐ERK1/2, and up‐regulates UBE2T (red arrows). (D) WB assay show that direct ERK activation (ERK agonist) increases UBE2T expression (red arrows), confirming ERK as a convergent effector. (E) BA does not alter Notch signalling, and DLL4‐Fc–induced Notch activation shows no impact on UBE2T. β‐Actin served as loading controls of total protein, and Lamin B1 for nuclear extracts. (F–H) The relative mRNA levels of UBE2T are detected by qPCR in U87MG (F), LN229 (G) and U251 glioma cell lines (H) additionally treated with agonists of the pathway mentioned above. “*” indicates significant difference compared with BA+CDDP group.
Igf 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igf 1/product/MedChemExpress
Average 93 stars, based on 1 article reviews
igf 1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
mouse recombinant igf-1 protein  (Thermo Fisher)
90
Thermo Fisher mouse recombinant igf-1 protein
Effects of BA on YY1/FAS, ERβ, <t>insulin/IGF‐1,</t> MAPK/ERK, and Notch signalling pathways regulating UBE2T expression in glioma cells. (A) WB assay show that BA suppresses the YY1/FAS axis, decreasing cleaved caspase‐8 and YY1 nuclear accumulation (red arrows); FASL co‐treatment failed to restore UBE2T (black arrows). (B) WB assay show that BA inhibits ERβ nuclear localization and ERK1/2 phosphorylation (red arrows); ERβ activation by DPN re‐stimulated p‐ERK1/2 and elevated UBE2T (red arrows). (C) WB assay show that the insulin/IGF‐1 pathway is unaffected by BA (black arrows), but IGF‐1 treatment enhances IGF‐1Rβ phosphorylation, increases p‐ERK1/2, and up‐regulates UBE2T (red arrows). (D) WB assay show that direct ERK activation (ERK agonist) increases UBE2T expression (red arrows), confirming ERK as a convergent effector. (E) BA does not alter Notch signalling, and DLL4‐Fc–induced Notch activation shows no impact on UBE2T. β‐Actin served as loading controls of total protein, and Lamin B1 for nuclear extracts. (F–H) The relative mRNA levels of UBE2T are detected by qPCR in U87MG (F), LN229 (G) and U251 glioma cell lines (H) additionally treated with agonists of the pathway mentioned above. “*” indicates significant difference compared with BA+CDDP group.
Mouse Recombinant Igf 1 Protein, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse recombinant igf-1 protein/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
mouse recombinant igf-1 protein - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
recombinant igf 1 protein  (Proteintech)
94
Proteintech recombinant igf 1 protein
Effects of BA on YY1/FAS, ERβ, <t>insulin/IGF‐1,</t> MAPK/ERK, and Notch signalling pathways regulating UBE2T expression in glioma cells. (A) WB assay show that BA suppresses the YY1/FAS axis, decreasing cleaved caspase‐8 and YY1 nuclear accumulation (red arrows); FASL co‐treatment failed to restore UBE2T (black arrows). (B) WB assay show that BA inhibits ERβ nuclear localization and ERK1/2 phosphorylation (red arrows); ERβ activation by DPN re‐stimulated p‐ERK1/2 and elevated UBE2T (red arrows). (C) WB assay show that the insulin/IGF‐1 pathway is unaffected by BA (black arrows), but IGF‐1 treatment enhances IGF‐1Rβ phosphorylation, increases p‐ERK1/2, and up‐regulates UBE2T (red arrows). (D) WB assay show that direct ERK activation (ERK agonist) increases UBE2T expression (red arrows), confirming ERK as a convergent effector. (E) BA does not alter Notch signalling, and DLL4‐Fc–induced Notch activation shows no impact on UBE2T. β‐Actin served as loading controls of total protein, and Lamin B1 for nuclear extracts. (F–H) The relative mRNA levels of UBE2T are detected by qPCR in U87MG (F), LN229 (G) and U251 glioma cell lines (H) additionally treated with agonists of the pathway mentioned above. “*” indicates significant difference compared with BA+CDDP group.
Recombinant Igf 1 Protein, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant igf 1 protein/product/Proteintech
Average 94 stars, based on 1 article reviews
recombinant igf 1 protein - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

Image Search Results


Effects of BA on YY1/FAS, ERβ, insulin/IGF‐1, MAPK/ERK, and Notch signalling pathways regulating UBE2T expression in glioma cells. (A) WB assay show that BA suppresses the YY1/FAS axis, decreasing cleaved caspase‐8 and YY1 nuclear accumulation (red arrows); FASL co‐treatment failed to restore UBE2T (black arrows). (B) WB assay show that BA inhibits ERβ nuclear localization and ERK1/2 phosphorylation (red arrows); ERβ activation by DPN re‐stimulated p‐ERK1/2 and elevated UBE2T (red arrows). (C) WB assay show that the insulin/IGF‐1 pathway is unaffected by BA (black arrows), but IGF‐1 treatment enhances IGF‐1Rβ phosphorylation, increases p‐ERK1/2, and up‐regulates UBE2T (red arrows). (D) WB assay show that direct ERK activation (ERK agonist) increases UBE2T expression (red arrows), confirming ERK as a convergent effector. (E) BA does not alter Notch signalling, and DLL4‐Fc–induced Notch activation shows no impact on UBE2T. β‐Actin served as loading controls of total protein, and Lamin B1 for nuclear extracts. (F–H) The relative mRNA levels of UBE2T are detected by qPCR in U87MG (F), LN229 (G) and U251 glioma cell lines (H) additionally treated with agonists of the pathway mentioned above. “*” indicates significant difference compared with BA+CDDP group.

Journal: Journal of Cellular and Molecular Medicine

Article Title: Betulinic Acid Suppresses UBE2T Expression via MAPK / ERK Inhibition to Block FANCI and FANCD2 Monoubiquitination in Glioblastoma

doi: 10.1111/jcmm.71000

Figure Lengend Snippet: Effects of BA on YY1/FAS, ERβ, insulin/IGF‐1, MAPK/ERK, and Notch signalling pathways regulating UBE2T expression in glioma cells. (A) WB assay show that BA suppresses the YY1/FAS axis, decreasing cleaved caspase‐8 and YY1 nuclear accumulation (red arrows); FASL co‐treatment failed to restore UBE2T (black arrows). (B) WB assay show that BA inhibits ERβ nuclear localization and ERK1/2 phosphorylation (red arrows); ERβ activation by DPN re‐stimulated p‐ERK1/2 and elevated UBE2T (red arrows). (C) WB assay show that the insulin/IGF‐1 pathway is unaffected by BA (black arrows), but IGF‐1 treatment enhances IGF‐1Rβ phosphorylation, increases p‐ERK1/2, and up‐regulates UBE2T (red arrows). (D) WB assay show that direct ERK activation (ERK agonist) increases UBE2T expression (red arrows), confirming ERK as a convergent effector. (E) BA does not alter Notch signalling, and DLL4‐Fc–induced Notch activation shows no impact on UBE2T. β‐Actin served as loading controls of total protein, and Lamin B1 for nuclear extracts. (F–H) The relative mRNA levels of UBE2T are detected by qPCR in U87MG (F), LN229 (G) and U251 glioma cell lines (H) additionally treated with agonists of the pathway mentioned above. “*” indicates significant difference compared with BA+CDDP group.

Article Snippet: Recombinant human IGF‐1 (MedChemExpress, Cat. No. HY‐ P70698 ) was used at 50 ng/mL for 30 min [ ].

Techniques: Expressing, Phospho-proteomics, Activation Assay